{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(4)"],"submitter":["Li Y"],"pubmed_abstract":["<h4>Background</h4>Lung cancer is a malignant tumor with the highest morbidity and mortality rates worldwide, of which lung adenocarcinoma (LUAD) is the most common subtype. Overall, current treatments of LUAD are not satisfactory; therefore, novel targets need to be explored. Let-7b-3p is an important member of the let-7 family of microRNAs (miRNAs), and has not been studied separately in LUAD. This study aimed to investigate the role and molecular mechanism of let-7b-3p in LUAD.<h4>Methods</h4>Herein, let-7b-3p expression was detected by quantitative real-time polymerase chain reaction (qRT-PCR) and fluorescence <i>in situ</i> hybridization (FISH) assays. MTT, colony formation assay, flow cytometry analysis, wound-healing, Transwell and <i>in vivo</i> experiments were conducted to assess let-7b-3p's function in LUAD. The downstream target TFIIB-related factor 2 (BRF2) was predicted using bioinformatics analyses and confirmed by dual-luciferase reporter assay and rescue experiments. Additionally, BRF2 was found to affect the MAPK/ERK pathway through transcriptome sequencing analysis and western blot (WB) assay.<h4>Results</h4>Let-7b-3p is downregulated in LUAD cells and tissue samples and low let-7b-3p expression is correlated with a poor prognosis in LUAD patients. Let-7b-3p suppresses the proliferation and metastasis of LUAD cells both <i>in vivo</i> and <i>in vitro</i> by directly targeting the BRF2-mediated MAPK/ERK pathway.<h4>Conclusions</h4>Let-7b-3p inhibits the development of LUAD and is an ideal novel therapeutic target for the treatment of LUAD."],"journal":["Translational lung cancer research"],"pagination":["1841-1856"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8107730"],"repository":["biostudies-literature"],"pubmed_title":["Let-7b-3p inhibits tumor growth and metastasis by targeting the BRF2-mediated MAPK/ERK pathway in human lung adenocarcinoma."],"pmcid":["PMC8107730"],"pubmed_authors":["Cheng C","Renaud S","Jiang J","Li Y","Lu M","Feng Z","Zhao R","Tian H","Liang J","Han J","Xu-Welliver M","Dong R"],"additional_accession":[]},"is_claimable":false,"name":"Let-7b-3p inhibits tumor growth and metastasis by targeting the BRF2-mediated MAPK/ERK pathway in human lung adenocarcinoma.","description":"<h4>Background</h4>Lung cancer is a malignant tumor with the highest morbidity and mortality rates worldwide, of which lung adenocarcinoma (LUAD) is the most common subtype. Overall, current treatments of LUAD are not satisfactory; therefore, novel targets need to be explored. Let-7b-3p is an important member of the let-7 family of microRNAs (miRNAs), and has not been studied separately in LUAD. This study aimed to investigate the role and molecular mechanism of let-7b-3p in LUAD.<h4>Methods</h4>Herein, let-7b-3p expression was detected by quantitative real-time polymerase chain reaction (qRT-PCR) and fluorescence <i>in situ</i> hybridization (FISH) assays. MTT, colony formation assay, flow cytometry analysis, wound-healing, Transwell and <i>in vivo</i> experiments were conducted to assess let-7b-3p's function in LUAD. The downstream target TFIIB-related factor 2 (BRF2) was predicted using bioinformatics analyses and confirmed by dual-luciferase reporter assay and rescue experiments. Additionally, BRF2 was found to affect the MAPK/ERK pathway through transcriptome sequencing analysis and western blot (WB) assay.<h4>Results</h4>Let-7b-3p is downregulated in LUAD cells and tissue samples and low let-7b-3p expression is correlated with a poor prognosis in LUAD patients. Let-7b-3p suppresses the proliferation and metastasis of LUAD cells both <i>in vivo</i> and <i>in vitro</i> by directly targeting the BRF2-mediated MAPK/ERK pathway.<h4>Conclusions</h4>Let-7b-3p inhibits the development of LUAD and is an ideal novel therapeutic target for the treatment of LUAD.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2025-04-27T00:16:47.402Z","creation":"2025-04-06T17:46:44.563Z"},"accession":"S-EPMC8107730","cross_references":{"pubmed":["34012797"],"doi":["10.21037/tlcr-21-299"]}}